Press Releases May 14, 2026 06:15 PM

Webcast Alert: Cavco Industries, Inc. Announces Fiscal 2026 Fourth Quarter and Year End Earnings Release and Conference Call Webcast

Cavco Industries schedules fiscal Q4 and year-end earnings release and webcast conference call

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
CVCO

Cavco Industries, a leading U.S. factory-built housing producer, announced its fiscal 2026 fourth quarter and full-year earnings release set for May 21, 2026, with a live webcast and conference call featuring senior management scheduled for May 22, 2026. Investors can listen via internet or telephone, with replay available for 90 days. Cavco operates across manufactured and modular homes, park model RVs, vacation cabins, and commercial structures, alongside mortgage and insurance subsidiaries.

Webcast Alert: Cavco Industries, Inc. Announces Fiscal 2026 Fourth Quarter and Year End Earnings Release and Conference Call Webcast
CVCO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Cavco Industries will release fiscal 2026 Q4 and year-end earnings after market close on May 21, 2026.
  • Senior management will present results in a webcast and conference call on May 22, 2026.
  • Company is a major U.S. producer in factory-built housing and related mortgage and insurance services.
  • Sectors impacted include housing construction, manufactured housing, finance (mortgage lending), and insurance for manufactured homes.

Phoenix, May 14, 2026 (GLOBE NEWSWIRE) -- Cavco Industries, Inc. (Nasdaq: CVCO) will release earnings for the fourth quarter and fiscal year ended March 28, 2026 on Thursday, May 21, 2026 after the close of market. Senior management will discuss the results in a live webcast the following day, Friday, May 22, 2026 at 1:00 p.m. Eastern Time.

Date: May 22, 2026

Time: 1:00 p.m. ET
        
Listen via Internet: https://investor.cavco.com/

Listen via Telephone: To participate in the call, please register here to receive the dial-in number and your unique PIN.

If you are unable to participate during the live webcast, the call will be available for 90 days on https://investor.cavco.com/.

Cavco Industries, Inc., headquartered in Phoenix, Arizona, designs and produces factory-built housing products primarily distributed through a network of independent and Company-owned retailers. We are one of the largest producers of manufactured and modular homes in the United States, based on reported wholesale shipments. We are also a leading producer of park model RVs, vacation cabins and factory-built commercial structures. Cavco's finance subsidiary, CountryPlace Mortgage, is an approved Fannie Mae and Freddie Mac seller/servicer and a Ginnie Mae mortgage-backed securities issuer that offers conforming mortgages, non-conforming mortgages and home-only loans to purchasers of factory-built homes. Our insurance subsidiary, Standard Casualty, provides property and casualty insurance to owners of manufactured homes.


Risks

  • Earnings results may reveal operational or financial risks affecting housing demand or manufacturing costs.
  • Broader housing market fluctuations and economic conditions could impact future performance.
  • Regulatory or market challenges for mortgage lending or insurance services related to factory-built housing may present uncertainties.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026